By Michael Dabaie


Dicerna Pharmaceuticals Inc. said Roche initiated RG6346 in a Phase 2 combination trial for the treatment of chronic hepatitis B virus infection, triggering a $25 million milestone to Dicerna.

RG6346 is an investigational therapeutic that Dicerna is developing in collaboration with Roche as part of the companies' collaboration and licensing agreement for chronic HBV treatments.

The Phase 2 platform trial will evaluate the efficacy and safety of RG6346 in combination with multiple additional agents with different mechanisms of action.

"We are very encouraged by the results from the Phase 1 trial of RG6346, which have shown a strong and sustained reduction in the levels of hepatitis B surface antigen," said John Young, global head of infectious diseases at Roche Pharmaceutical Research and Early Development.


Write to Michael Dabaie at


(END) Dow Jones Newswires

March 04, 2021 09:15 ET (14:15 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.